185 related articles for article (PubMed ID: 33635217)
1. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis.
Sözeri B; Kardeş E; Salı E; Çakır D; Demir F
Clin Exp Rheumatol; 2021; 39(4):907-912. PubMed ID: 33635217
[TBL] [Abstract][Full Text] [Related]
2. Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis.
Morita A; Nishikawa K; Yamada F; Yamanaka K; Nakajima H; Ohtsuki M
J Dermatol; 2022 Oct; 49(10):957-969. PubMed ID: 35799412
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.
Sagami S; Nishikawa K; Yamada F; Suzuki Y; Watanabe M; Hibi T
J Gastroenterol Hepatol; 2021 Aug; 36(8):2091-2100. PubMed ID: 33450057
[TBL] [Abstract][Full Text] [Related]
5. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
Takeuchi T; Nishikawa K; Yamada F; Ohshima S; Inoue M; Yoshioka Y; Yamanaka H
Mod Rheumatol; 2022 Jul; 32(4):718-727. PubMed ID: 34918129
[TBL] [Abstract][Full Text] [Related]
6. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
[TBL] [Abstract][Full Text] [Related]
7. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Pranzo G; Rodinò S; Scarcelli A; Zampaletta C; Brozzi L; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Fiorella S; Iannelli C; Larussa T; Le Grazie M; Luppino I; Meucci C; FaggianI R; Pagnini C; Perazzo P; Rodriguez-Castro KI; Sacco R; Sebkova L; Serio M; De Monti A; Picchio M; Napolitano D; Schiavoni E; Turchini L; Scaldaferri F; Pugliese D; Guidi L; Laterza L; Privitera G; Pizzoferrato M; Lopetuso LR; Armuzzi A; Elisei W; Maconi G; Papa A
Expert Opin Biol Ther; 2022 Feb; 22(2):313-320. PubMed ID: 34904510
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety.
Dipasquale V; Romano C
J Clin Pharm Ther; 2020 Dec; 45(6):1228-1234. PubMed ID: 32743840
[TBL] [Abstract][Full Text] [Related]
9. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
Cheon JH; Nah S; Kang HW; Lim YJ; Lee SH; Lee SJ; Kim SH; Jung NH; Park JE; Lee YJ; Jeon DB; Lee YM; Kim JM; Park SH
Adv Ther; 2021 Aug; 38(8):4366-4387. PubMed ID: 34250583
[TBL] [Abstract][Full Text] [Related]
10. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Shimizu T; Kawashiri SY; Sato S; Morimoto S; Minoda S; Kawazoe Y; Kuroda S; Tashiro S; Sumiyoshi R; Hosogaya N; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Aug; 99(32):e21480. PubMed ID: 32769882
[TBL] [Abstract][Full Text] [Related]
12. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients.
Pugliese D; Guidi L; Privitera G; Bertani L; Tolusso B; Papparella LG; Maltinti S; Di Mario C; Onali S; Ceccarelli L; Rapaccini GL; Scaldaferri F; Gremese E; Gasbarrini A; Costa F; Armuzzi A
Expert Opin Biol Ther; 2021 Jan; 21(1):97-104. PubMed ID: 33074723
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
[TBL] [Abstract][Full Text] [Related]
14. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
Ebada MA; Elmatboly AM; Ali AS; Ibrahim AM; Fayed N; Faisal AF; Alkanj S
Int J Colorectal Dis; 2019 Oct; 34(10):1633-1652. PubMed ID: 31492986
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Yoo DH; Prodanovic N; Jaworski J; Miranda P; Ramiterre E; Lanzon A; Baranauskaite A; Wiland P; Abud-Mendoza C; Oparanov B; Smiyan S; Kim H; Lee SJ; Kim S; Park W
Ann Rheum Dis; 2017 Feb; 76(2):355-363. PubMed ID: 27130908
[TBL] [Abstract][Full Text] [Related]
17. Development of pulmonary sarcoidosis in Crohn's disease patient under infliximab biosimilar treatment after long-term original infliximab treatment: a case report and literature review.
Kashima S; Moriichi K; Ando K; Ueno N; Tanabe H; Yuzawa S; Fujiya M
BMC Gastroenterol; 2021 Oct; 21(1):373. PubMed ID: 34641810
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis.
Miraldi Utz V; Bulas S; Lopper S; Fenchel M; Sa T; Mehta M; Ash D; Lovell DJ; Kaufman AH
Pediatr Rheumatol Online J; 2019 Nov; 17(1):79. PubMed ID: 31783768
[TBL] [Abstract][Full Text] [Related]
19. Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies.
Lee SJ; Baek K; Lee S; Lee YJ; Park JE; Lee SG
BioDrugs; 2020 Aug; 34(4):513-528. PubMed ID: 32356239
[TBL] [Abstract][Full Text] [Related]
20. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry.
Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K
Clin Exp Rheumatol; 2020; 38(2):267-274. PubMed ID: 31365335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
